EGFR and non-small cell lung carcinoma: An exciting study by Gober et al. predicted a 13-miRNA signature for the response to the EGFR-TKI erlotinib in NSCLC cell lines and tumors and discriminated primarily from metastatic tumors [72,185,186,189].